Procter & Gamble Health (BOM:500126) ROCE %: 91.01% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:500126 Procter & Gamble Health Ltd BOM:500126
86 GF Score
Price ₹6,797.90
GF Value ₹6,049.27
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Procter & Gamble Health ROCE %?

Procter & Gamble Health BOM:500126 -0.76% 86 ROCE % is 91.01% as of Mar. 2026. GuruFocus rates BOM:500126 with a GF Score™ of 86/100 and a GF Value™ of ₹6,049.27 (Modestly Overvalued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Procter & Gamble Health's annualized ROCE % for the quarter that ended in Mar. 2026 was 91.01%.

Procter & Gamble Health  (BOM:500126) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Procter & Gamble Health ROCE % Related Terms

Procter & Gamble Health ROCE % Historical Data

* Premium members only.

The historical data trend for Procter & Gamble Health's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Procter & Gamble Health ROCE % Chart

Procter & Gamble Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Jun21 Jun22 Jun23 Jun24
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.46 29.42 36.17 43.34 39.93

Procter & Gamble Health Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 48.39 0.00 70.93 64.84 91.01
BOM:500126
86GF Score
Procter & Gamble Health Ltd BOM:500126
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Procter & Gamble Health ROCE % Calculation

Procter & Gamble Health's annualized ROCE % for the fiscal year that ended in Jun. 2024 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2024 )  (A: Jun. 2023 )(A: Jun. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2024 )  (A: Jun. 2023 )(A: Jun. 2024 )
=2740.4/( ( (11011.9 - 3039) + (7943.6 - 2189.1) )/ 2 )
=2740.4/( (7972.9+5754.5)/ 2 )
=2740.4/6863.7
=39.93 %

Procter & Gamble Health's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=5336.8/( ( (0 - 0) + (8413.5 - 2549.3) )/ 1 )
=5336.8/( ( 0 + 5864.2 )/ 1 )
=5336.8/5864.2
=91.01 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 91.01% mean?
Procter & Gamble Health (BOM:500126) has a ROCE % of 91.01% as of Mar. 2026.
Is Procter & Gamble Health's ROCE % too high?
Procter & Gamble Health's current ROCE % is 91.01%. The Drug Manufacturers industry median ROCE % is 7.05. Procter & Gamble Health's value of 91.01% is 1190.9% above this industry median. Overall, Procter & Gamble Health has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Procter & Gamble Health's ROCE % compare to ZTS and UTHR?
Procter & Gamble Health's ROCE % of 91.01% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.05. Procter & Gamble Health's value of 91.01% is 1190.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.05, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Procter & Gamble Health's current ROCE % of 91.01% is 1190.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Procter & Gamble Health's current ROCE % is 91.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Procter & Gamble Health stock overvalued right now?
Based on GuruFocus' analysis, Procter & Gamble Health (BOM:500126) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹6,049.27, compared to a current price of ₹6,797.90 — trading 12.4% above its estimated fair value. The current ROCE % is 91.01% and 1190.9% above the Drug Manufacturers industry median of 7.05. Procter & Gamble Health's overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Procter & Gamble Health (BOM:500126), the current ROCE % is 91.01% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Procter & Gamble Health (BOM:500126) Overvalued in 2026?

Based on GuruFocus' analysis, Procter & Gamble Health stock appears to be overvalued. The current stock price of ₹6,797.90 is trading 12.4% above its estimated GF Value™ of ₹6,049.27. GuruFocus considers Procter & Gamble Health to be Modestly Overvalued.

Key valuation signals for BOM:500126:

  • ROCE %: 91.01%
  • GF Value™: ₹6,049.27 vs. price of ₹6,797.90 (12.4% above fair value)
  • GF Score™: 86/100 with 6 warning signs
  • Industry Position: 1190.9% above the Drug Manufacturers median

No single metric tells the full story. See the BOM:500126 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Procter & Gamble Health Business Description

Other Exchanges PGHL:India
Address Cardinal Gracias Road, Ground Floor And First Floor, P&G Plaza, Chakala, Andheri East, Mumbai, MH, IND, 400099
Procter & Gamble Health Ltd is an India based pharmaceutical company engaged in manufacturing and selling of healthcare products, viz., vitamins, minerals and supplements. Patients are end consumers of the products. The Company's distribution channels (direct & indirect), inter alia, include distributors, health care professionals, pharmacies and chemists. Cosome, Evion, Neurobion, Nasivion, Polybion, Livogen and Seven Seas are some of the brands of the company. The geographical segments include sales in India and exports.
86GF Score

Get the complete analysis for BOM:500126

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹6,797.90
Price
₹6,049.27
GF Value